News
NRXPW
0.0070
-30.00%
-0.0030
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
TipRanks · 15h ago
NRx Pharmaceuticals announces incorporation of NRx Defense Systems
TipRanks · 15h ago
BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financial, Papa John's
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Gitlab, Snap, Robinhood
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, BofA, Snap
Reuters · 1d ago
BUZZ-NRx Pharmaceuticals rises as it launches defense-focused mental health unit
Reuters · 1d ago
NRx advances robotic TMS plus D-cycloserine neuroplastic therapy for military, responders
PUBT · 1d ago
NRX PHARMACEUTICALS INC: DEVELOPMENT INITIATIVE TO BE CONDUCTED THROUGH R&D UNIT NRX DEFENSE SYSTEMS, IN PARTNERSHIP WITH ZETA SURGICAL
Reuters · 1d ago
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
Barchart · 2d ago
NRx Pharmaceuticals appoints Glenn Tyson chief commercial officer
TipRanks · 3d ago
NRx Pharmaceuticals names Glenn Tyson as first chief commercial officer
PUBT · 3d ago
Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer
Dow Jones · 3d ago
Weekly Report: what happened at NRXP last week (0406-0410)?
Weekly Report · 3d ago
Psychedelic: AtaiBeckley reports publication of BPL-003 study results
TipRanks · 04/09 15:00
NRx Pharmaceuticals announces FDA labeling alignment for ketamine product
TipRanks · 04/06 11:18
NRx Pharmaceuticals Receives FDA Letter Regarding Comments On Minor Formatting Changes To Proposed Label For Its Preservative-Free Ketamine Product, The Company Expects To Submit Final Label In April
Benzinga · 04/06 11:05
NRX PHARMACEUTICALS (NASDAQ:NRXP) ANNOUNCES FDA LABELING ALIGNMENT FOR NRX’S PRESERVATIVE-FREE KETAMINE APPLICATION
Reuters · 04/06 11:00
Weekly Report: what happened at NRXP last week (0330-0403)?
Weekly Report · 04/06 10:01
Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
TipRanks · 04/02 13:55
More
Webull provides a variety of real-time NRXPW stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXPW
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.